Classification of cellular therapies for SARS-CoV-2 infection. Cellular therapy for SARS-CoV-2 can be classified as adoptive anti-viral immunotherapy with CST or NK cells to aid immunocompromised patients with viral clearance (A) or immunomodulatory immunotherapy with Tregs or MSCs to correct dysregulated immune responses in patients with severe COVID-19 (B).